Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection
Abstract Background Dalbavancin is a lipoglycopeptide antibiotic approved for treatment of skin and soft tissue infections, administered as a single or two-dose treatment. The extended half-life, good penetration into bone and synovial fluid, and bactericidal activity against gram-positive bacteria,...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-10-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12879-023-08709-8 |
| _version_ | 1797453762148696064 |
|---|---|
| author | Anna Lange Ulrica Thunberg Bo Söderquist |
| author_facet | Anna Lange Ulrica Thunberg Bo Söderquist |
| author_sort | Anna Lange |
| collection | DOAJ |
| description | Abstract Background Dalbavancin is a lipoglycopeptide antibiotic approved for treatment of skin and soft tissue infections, administered as a single or two-dose treatment. The extended half-life, good penetration into bone and synovial fluid, and bactericidal activity against gram-positive bacteria, including those in biofilm, make dalbavancin an appealing choice for treatment of bone and joint infections in outpatient settings. However, we present a rare case of ototoxicity associated with off-label extended dalbavancin treatment of a prosthetic joint infection. Case presentation A 55-year-old man with a prosthetic joint infection of the shoulder underwent off-label extended dalbavancin treatment, receiving a cumulative dose of 2500 mg. The patient experienced a gradual onset of hearing loss following the first dose, leading to a diagnosis of bilateral sensorineural hearing loss that persisted 1 year after dalbavancin was discontinued. Conclusions This case report highlights the importance of exercising caution when administering dalbavancin beyond approved dosing guidelines, and emphasizes the need for vigilance regarding the potential for ototoxicity. |
| first_indexed | 2024-03-09T15:27:32Z |
| format | Article |
| id | doaj.art-b44ed116cbdd4cbcaf6df8cd039a6b74 |
| institution | Directory Open Access Journal |
| issn | 1471-2334 |
| language | English |
| last_indexed | 2024-03-09T15:27:32Z |
| publishDate | 2023-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj.art-b44ed116cbdd4cbcaf6df8cd039a6b742023-11-26T12:27:03ZengBMCBMC Infectious Diseases1471-23342023-10-012311510.1186/s12879-023-08709-8Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infectionAnna Lange0Ulrica Thunberg1Bo Söderquist2Department of Infectious Diseases, Faculty of Medicine and Health, Örebro UniversityDepartment of Otorhinolaryngology, Faculty of Medicine and Health, Örebro UniversitySchool of Medical Sciences, Faculty of Medicine and Health, Örebro UniversityAbstract Background Dalbavancin is a lipoglycopeptide antibiotic approved for treatment of skin and soft tissue infections, administered as a single or two-dose treatment. The extended half-life, good penetration into bone and synovial fluid, and bactericidal activity against gram-positive bacteria, including those in biofilm, make dalbavancin an appealing choice for treatment of bone and joint infections in outpatient settings. However, we present a rare case of ototoxicity associated with off-label extended dalbavancin treatment of a prosthetic joint infection. Case presentation A 55-year-old man with a prosthetic joint infection of the shoulder underwent off-label extended dalbavancin treatment, receiving a cumulative dose of 2500 mg. The patient experienced a gradual onset of hearing loss following the first dose, leading to a diagnosis of bilateral sensorineural hearing loss that persisted 1 year after dalbavancin was discontinued. Conclusions This case report highlights the importance of exercising caution when administering dalbavancin beyond approved dosing guidelines, and emphasizes the need for vigilance regarding the potential for ototoxicity.https://doi.org/10.1186/s12879-023-08709-8DalbavancinProsthetic joint infectionOtotoxicity |
| spellingShingle | Anna Lange Ulrica Thunberg Bo Söderquist Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection BMC Infectious Diseases Dalbavancin Prosthetic joint infection Ototoxicity |
| title | Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection |
| title_full | Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection |
| title_fullStr | Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection |
| title_full_unstemmed | Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection |
| title_short | Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection |
| title_sort | ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection |
| topic | Dalbavancin Prosthetic joint infection Ototoxicity |
| url | https://doi.org/10.1186/s12879-023-08709-8 |
| work_keys_str_mv | AT annalange ototoxicityassociatedwithextendeddalbavancintreatmentforashoulderprostheticjointinfection AT ulricathunberg ototoxicityassociatedwithextendeddalbavancintreatmentforashoulderprostheticjointinfection AT bosoderquist ototoxicityassociatedwithextendeddalbavancintreatmentforashoulderprostheticjointinfection |